Table 2.
PCR positivity and seroconversion rates per vaccination group.
| Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | |
|---|---|---|---|---|---|
| Number of patients | 2144 | 1532 | 1283 | 147 | 40 |
| Positive PCR over the past period | 102 (5.1%) | 87 (5.9%) | 263 (20.5%) | 42 (28.6%) | 18 (45%) |
| N-antibody seroconversion | 65/2108 (3.1%) | 35/1481 (2.4%) | 189/1240 (15.2%) | 26/143 (18.2%) | 9/39 (23.1%) |
| Ever had SARS-CoV-2 infection * | 121 (5.7%) | 131 (8.6%) | 371 (28.9%) | 57 (38.8%) | 20 (50%) |
| S-antibody seroconversion | Not tested | 1303/1370 (95.1%) | 1216/1240 (98.1%) | 143/143 (100%) | 21/39 (53.8%) |
| S (−)/N (−) | N.A | 66/1370 (4.8%) | 24/1240 (1.9%) | 0 | 16/39 (41.0%) |
| S (−)/N (+) | N.A | 1/1370 (0.1%) | 0 | 0 | 2/39 (5.1%) |
| S (+)/N (−) | N.A | 1273/1370 (92.9%) | 1027/1240 (82.8%) | 117/143 (81.8%) | 14/39 (35.9%) |
| S (+)/N (+) | N.A | 30/1270 (2.2%) | 189/1240 (15.2%) | 26/143 (18.2%) | 7/39 (17.9%) |
Abbreviations: N: nucleocapsid protein, S: spike protein, (−): no seroconversion, (+) seroconversion, N.A: not applicable. * Based on N-seroconversion and/or PCR positivity.